VYGR Q3'26 Revenue Estimate Is 6.35M USD
Voyager Therapeutics is set to report Q3'26 results on November 10; the report time is unspecified. Revenue is estimated at 6.35 million USD and EPS at (0.42) USD.
Related stories
SOPHiA GENETICS Reports Q3 2026 Revenue Growth and Reaffirms Outlook
Revenue rose 25% year over year to $24.3 million. The company expects 2026 revenue at the upper end of its $94 million to $96 million guidance range.
M impact | EQUITY | Nov 03, 2026, 04:33 PM UTC
Opera Reports Q3 Revenue of $182.8 Million, Adjusted EBITDA of $43.2 Million
Opera said revenue rose 20% year over year to $182.8 million, at the top of its $181–183 million guidance range. Adjusted EBITDA was $43.2 million, above its $41–43 million guidanc
M impact | EQUITY | Nov 03, 2026, 04:33 PM UTC
ChemoMetec Raises 2026/27 Guidance, Reports Preliminary Q1 Results
ChemoMetec lifted revenue guidance to DKK 570–605 million from DKK 560–590 million and EBITDA guidance to DKK 335–360 million from DKK 330–345 million. Preliminary Q1 revenue rose
M impact | EQUITY | Nov 03, 2026, 04:33 PM UTC
Palantir Raises 2026 Revenue Guidance After Q3 Revenue Climbs 96%
Palantir reported Q3 revenue of $2.313B, up 96% year over year, and raised full-year 2026 revenue guidance to $8.530B—$8.534B. U.S. commercial revenue was $984M, up 148%.
M impact | EQUITY | Nov 03, 2026, 04:32 PM UTC
Toyota Motor North America U.S. Electrified Sales Rise 34.6% in October
Toyota Motor North America reported 126,054 U.S. electrified vehicle sales in October 2026, up 34.6% on a volume basis.
M impact | EQUITY | Nov 03, 2026, 04:32 PM UTC
Dow Falls While Nasdaq Rises in Election Day Trading
Tuesday’s session reversed the previous pattern, with the Dow lower and the Nasdaq higher.
M impact | EQUITY | Nov 03, 2026, 04:32 PM UTC